JP2007533655A5 - - Google Patents

Download PDF

Info

Publication number
JP2007533655A5
JP2007533655A5 JP2006539641A JP2006539641A JP2007533655A5 JP 2007533655 A5 JP2007533655 A5 JP 2007533655A5 JP 2006539641 A JP2006539641 A JP 2006539641A JP 2006539641 A JP2006539641 A JP 2006539641A JP 2007533655 A5 JP2007533655 A5 JP 2007533655A5
Authority
JP
Japan
Prior art keywords
methoxy
amino
methoxyphenyl
dichloro
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006539641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/036722 external-priority patent/WO2005046693A1/en
Publication of JP2007533655A publication Critical patent/JP2007533655A/ja
Publication of JP2007533655A5 publication Critical patent/JP2007533655A5/ja
Pending legal-status Critical Current

Links

JP2006539641A 2003-11-06 2004-11-03 慢性骨髄性白血病(cml)の治療のための4−アニリノ−3−キノリンカルボニトリル Pending JP2007533655A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06
PCT/US2004/036722 WO2005046693A1 (en) 2003-11-06 2004-11-03 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Publications (2)

Publication Number Publication Date
JP2007533655A JP2007533655A (ja) 2007-11-22
JP2007533655A5 true JP2007533655A5 (https=) 2008-01-10

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539641A Pending JP2007533655A (ja) 2003-11-06 2004-11-03 慢性骨髄性白血病(cml)の治療のための4−アニリノ−3−キノリンカルボニトリル

Country Status (18)

Country Link
US (2) US7417148B2 (https=)
EP (1) EP1680119A1 (https=)
JP (1) JP2007533655A (https=)
KR (1) KR20060118461A (https=)
CN (1) CN1874776A (https=)
AU (1) AU2004289243B2 (https=)
BR (1) BRPI0416289A (https=)
CA (1) CA2543163A1 (https=)
CO (1) CO5690608A2 (https=)
CR (1) CR8350A (https=)
EC (1) ECSP066548A (https=)
IL (1) IL175424A0 (https=)
MX (1) MXPA06004744A (https=)
NO (1) NO20062255L (https=)
RU (1) RU2006113691A (https=)
SG (1) SG146681A1 (https=)
WO (1) WO2005046693A1 (https=)
ZA (1) ZA200603596B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
CN103705517A (zh) 2005-06-17 2014-04-09 得克萨斯大学体系董事会 Src激酶抑制剂对溶骨性病变的抑制
CN101252931A (zh) * 2005-06-24 2008-08-27 惠氏公司 用于治疗癌症的4-苯胺基-3-喹啉甲腈
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
CA2964162C (en) * 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2015123758A1 (en) 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
EP3246046A4 (en) 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
EP3953450A1 (en) 2019-04-09 2022-02-16 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Similar Documents

Publication Publication Date Title
JP2007533655A5 (https=)
JP6021805B2 (ja) 腫瘍治療剤
JP2006514626A5 (https=)
RU2006113691A (ru) Применение 4-анилин-3-хинолинкарбонитрилов для лечения хронической миелогенной лейкемии (cml)
JP2005533860A5 (https=)
TNSN07050A1 (fr) Derives de triazolopyridinylsulfanyle servant d'inhibiteurs de kinase map p38
JP2004508357A5 (https=)
JP2002534508A5 (https=)
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2010526814A5 (https=)
JP2010501478A5 (https=)
JP2012502017A5 (https=)
JP2008515913A5 (https=)
JP2004517049A5 (https=)
JP2005531488A5 (https=)
JP2004524316A5 (https=)
JP2002030084A5 (https=)
JP2006508953A5 (https=)
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
JP2005536503A5 (https=)
JP2012507535A5 (https=)
JP2015503596A5 (https=)
JP2005500370A5 (https=)
JP2008534453A5 (https=)
CN115315423A (zh) 取代芳基类化合物